.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,978,698

« Back to Dashboard
Patent 5,978,698 protects AGGRASTAT and is included in two NDAs.

This patent has three patent family members in one country.

Summary for Patent: 5,978,698

Title: Angioplasty procedure using nonionic contrast media
Abstract:A method for treating patients in need of percutaneous transluminal coronary angioplasty which comprises administering nonionic contract media to the patient and treating the patient with a fibrinogen receptor antagonist.
Inventor(s): Sax; Frederic L. (Villanova, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/943,872
Patent Claim Types:
see list of patent claims
Use;
Patent Metrics:
Source: PatentQuant.com
Field: Medical technology
Back Citations: 2nd percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Medicure
AGGRASTAT
tirofiban hydrochloride
INJECTABLE;INJECTION020912-001May 14, 1998DISCNNo5,978,698► subscribe
Medicure
AGGRASTAT
tirofiban hydrochloride
SOLUTION;INJECTION020912-002Aug 31, 2016RXYes5,978,698► subscribe
Medicure
AGGRASTAT
tirofiban hydrochloride
INJECTABLE;INJECTION020913-002May 17, 2002RXNo5,978,698► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,978,698

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
United Kingdom2318053► subscribe
United Kingdom9626396► subscribe
United Kingdom9720996► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc